SEAL Therapeutics AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SEAL Therapeutics AG
Tech Transfer Roundup: Santhera Exits Congenital Muscular Dystrophy Pact To Focus On DMD
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.